Better Health for All

Cytek Biosciences' core products, including flow cytometers, panels, and reagents, are advanced research tools that enable deep immunophenotyping, biomarker discovery, and comprehensive cell analysis.

These tools are used in studies for infectious and autoimmune diseases, cancer monitoring, and drug development, contributing to a deeper understanding of immunology and potentially altering drug discovery and efficacy. Over 2,100 peer-reviewed articles have been published using their products, indicating their widespread use in health-positive research. The company's products are research tools and do not have direct negative health outcomes or safety implications for physical or mental health. Cytek offers an affordable Muse Micro system, launched in March 2024, designed to make flow cytometry accessible to smaller labs, emerging markets, and resource-limited facilities. The company's microcapillary fluidics design eliminates sheath fluid and reduces waste.

Fair Money & Economic Opportunity

Cytek Biosciences, Inc. is a biotechnology company specializing in cell analysis solutions, not a financial institution.

Its core business involves developing and commercializing flow cytometry instrumentation, reagents, and software. Therefore, all KPIs related to financial services, such as lending practices, fee structures, financial inclusion initiatives, and customer financial outcomes, are not applicable to its operations. The provided articles contain no data on financial inclusion, lending practices, or community reinvestment, which is consistent with the company's business model outside of finance.

Fair Pay & Worker Respect

The estimated ratio of the Chief Executive Officer's annual total compensation to the median employee's annual total compensation was 48.1 to 1.

All full-time employees are eligible to participate in health and welfare benefit programs, including medical, dental, and vision care coverage, disability, and life insurance. The company also offers a 401(k) plan with a company match, which became fully vested for all employees starting January 1, 2024. As of December 31, 2021, the company had 502 employees, none of whom were represented by a labor union or party to a collective bargaining agreement. The company states it is an equal-opportunity employer and promotes workplace safety by encouraging reporting of hazards and unsafe conditions. An employee engagement survey was part of individual performance objectives for a leader, but no score was provided.

Fair Trade & Ethical Sourcing

Cytek Biosciences states it is not aware of any modern slavery or forced labor issues as of April 20, 2023.

The company's supplier agreements require compliance with local laws and regulations, including those related to modern slavery, human trafficking, and child labor. For conflict minerals, Cytek's Form SD for 2024 indicates that a small number of suppliers acknowledged the presence of 3TG Minerals without being able to identify their source or the status of the smelters or refiners, or reported sourcing from identified smelters without confirmation of their Responsible Mineral Assurance Process (RMAP) status. Some suppliers also failed to respond or provide complete responses to supply-chain surveys. The company's supplier contracts include clauses requiring compliance with various laws and regulations, such as the California Transparency in Supply Chains Act, the EU Directive 2011/36/EU, and the UK Modern Slavery Act 2015, as well as anti-corruption laws.

Honest & Fair Business

Cytek Biosciences, Inc. has a confidential and anonymous financial concern hotline for complaints regarding accounting, internal accounting controls, or auditing matters.

This hotline offers secure web form and submission options, with messages encrypted and delivered to the General Counsel and Audit Committee. A 14-16 digit code is provided for message status tracking, indicating that reports are acknowledged and tracked. The SEC requires the company to facilitate the receipt, retention, and treatment of such complaints.

Kind to Animals

Cytek Biosciences Inc. is listed as having "No Animal Exploitation" by crueltyfreeinvesting.org.

This indicates that the company uses zero animals in testing. While the article does not provide details on historical data disclosure or external audits, the categorical statement of no animal exploitation aligns with the positive tiers for animal testing volume.

No War, No Weapons

The provided article focuses on Cytek Biosciences' general ESG initiatives but does not contain any specific quantitative data, regulatory actions, certifications, or other facts relevant to the 'No War, No Weapons' ethical value.

Therefore, no KPIs can be scored based on the available evidence.

Planet-Friendly Business

The company has no reported environmental compliance violations, regulatory actions, or fines.

There is no publicly available quantitative data for any other environmental KPIs, including carbon emissions, reduction targets, renewable energy usage, water consumption, or waste diversion.

Zero Waste & Sustainable Products

The provided articles offer no specific, quantifiable evidence regarding Cytek Biosciences' performance across any of the 'Zero Waste & Sustainable Products' KPIs. While one article mentions the company is 'working to minimize the environmental effects of our operations'

and another notes 'collaboration with environmentally friendly packaging solutions,' these are general statements of intent or activity and do not provide concrete data, initiatives, or outcomes that can be scored against the rubric's specific quantitative thresholds. Therefore, all KPIs for this value must be omitted due to a lack of explicit, measurable facts.